Oncotarget

Researchers Kevin C. Ma, Esther Mena, Liza Lindenberg, Nathan S. Lay, and others introduce an AI tool for attenuation-corrected PET images in prostate cancer imaging, reducing reliance on CT scans and patient radiation exposure. The deep learning algorithm successfully generates AC PET images, enhancing diagnostic confidence and patient care.

Researchers from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC) and the impact on chemotherapy resistance. They highlight ABCB1's role in multidrug resistance and poor prognosis. The podcast explores the potential of targeting ABCB1 as a therapeutic strategy to overcome drug resistance in patients.

Research paper explores the combination of TAS-102 and Regorafenib for treating gastrointestinal cancers with promising anti-tumor effects in preclinical studies, providing a potential new treatment approach for advanced GI cancers.

Laurène Fenwarth, a molecular researcher from the University of Lille, and Nicolas Duployez, an expert in acute myeloid leukemias from CHU Lille, share their insights on the evolving role of genomics in cancer treatment. They discuss how molecular and cytogenetic analyses reveal new mutations that aid in classifying acute myeloid leukemias and myelodysplastic syndromes. Despite significant advancements, 15% of AML cases remain genetically unclassifiable. Their discussion highlights the need for continued research and innovative bioinformatics to tackle these challenges.

Researchers discuss a novel therapeutic strategy for prostate cancer involving the depletion of cysteine to induce oxidative stress and DNA damage, enhancing the efficacy of DNA repair targeted and immune checkpoint blockade therapies.

Duke University researchers discuss leveraging gold nanostars for precision laser interstitial thermal therapy to improve treatment for brain tumors. They explore the limitations of current methods and how utilizing nanostars can enhance precision, efficiency, and safety in the procedure.

Exploring the challenges of using dual immunotherapies in HR+/HER2-negative breast cancer patients, focusing on amplifying tumor-infiltrating lymphocytes through dual checkpoint inhibition before surgery and chemotherapy. Highlighting the importance of biomarkers like PDL1 expression and tumor mutation burden in improving treatment outcomes and reducing toxicity.

Researchers from Schulich School of Medicine discuss the role of CEA, CA-125, and CA19-9 as adjuncts in NSCLC management. They analyze associations with radiographic responses and clinical outcomes in NSCLC patients. The study provides evidence for the clinical use of these tumor markers in guiding treatment decisions.

Researchers John F. Thompson and Gabrielle J. Williams discuss the timing of treatment for melanoma, emphasizing the importance of identifying high-risk patients early. They explore the implications of offering adjuvant therapy to patients whose melanoma may have already metastasized for better treatment outcomes.

BUFFALO, NY- June 11, 2024 – The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 28 years to celebrate cancer survivors, pay tribute to lives that have been lost, and to work together to support research and find a cure. THE ORIGIN OF THE RIDE The Ride for Roswell started in 1989 when Mitch Flynn, owner of the advertising agency Flynn & Friends, met Katherine Gioia. Katherine was a four-year-old patient battling a rare form of cancer. After Katherine’s death (less than a year after her diagnosis), Katherine’s mother, Anne Gioia, and aunt, Donna Gioia, founded the Roswell Park Alliance Foundation in her memory to raise money for cancer research and treatment. On June 29, 1996, Mitch and Alliance Foundation staff launched the first Ride for Roswell. In the 28 years since then, thanks to over 135,000 riders and thousands of volunteers, the Ride for Roswell has raised over $72 million to fund cancer research. The event has become one of the largest charity rides in the United States. THIS YEAR This year, Ride Day is on Saturday, June 22, 2024, and will once again begin at the University at Buffalo North Campus. There are nine routes to choose from, ranging from five to 100 mile distances. All riders are encouraged to check in on the Thursday or Friday before Ride Day. Learn more about The Ride, check in, and routes: www.rideforroswell.org/routes/ JOIN A TEAM: TEAM OPEN ACCESS Impact Journals has been a part of this event since 2018 and continues to sponsor captain Sergei Kurenov’s peloton, Team Open Access. Team Open Access was named in honor of all open-source online medical journals, such as Oncotarget, Aging, Genes & Cancer, and Oncoscience. Sergei works at Roswell Park Comprehensive Cancer Center to create, develop, and implement innovative diagnostic and surgical pre-planning software used in cancer treatment. He has been riding in the event since 2016. “I am proud to [say] that our team is supported again by open source cancer-related scientific journals: Oncotarget and Aging! Both of these journals publish high-impact research papers of general interest and biological significance in all fields of cancer research,” Sergei said. There is still time to join Team Open Access in the Ride for Roswell. You can also support the team by giving a donation of any size. Any avenue of support you may choose to donate to the Ride for Roswell will make a difference and change lives. “Finding a cure for cancer is something we are all incredibly passionate about, and we are so thankful and grateful for your support. Together, we can make a difference!” Sergei said. “Thank you so much for your donations, your support, and well wishes!” Visit the Open Access team page to join or donate today: give.roswellpark.org/site/TR/Specia…eam&fr_id=1940 For media requests, please contact media@impactjournals.com.